Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled and Multicenter Phase Ⅱ Clinical Trials To Evaluate the Safety, Efficacy and Pharmacokinetics of GST-HG141 Tablets in Treated Chronic Hepatitis B (CHB) Patients With Low Viremia

NCT05637541 is registered in ClinicalTrials.gov with Fujian Akeylink Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05637541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05637541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled and Multicenter Phase Ⅱ Clinical Trials To Evaluate the Safety, Efficacy and Pharmacokinetics of GST-HG141 Tablets in Treated Chronic Hepatitis B (CHB) Patients With Low Viremia
Lead sponsor
Fujian Akeylink Biotechnology Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
January 3, 2023
Completion date
August 24, 2024
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b